- MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
- MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
- MediWound to Participate in Two Upcoming Investor Conferences
- MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
- MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
- MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
- MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
- MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
- MediWound to Report Third Quarter 2023 Financial Results
More ▼
Key statistics
As of last trade Mediwound Ltd (MDWD:NMQ) traded at 17.53, -6.51% below its 52-week high of 18.75, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.26 |
---|---|
High | 17.73 |
Low | 16.26 |
Bid | 17.48 |
Offer | 17.67 |
Previous close | 16.41 |
Average volume | 94.34k |
---|---|
Shares outstanding | 9.49m |
Free float | 7.05m |
P/E (TTM) | -- |
Market cap | 155.76m USD |
EPS (TTM) | -0.768 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 20:10 BST.
More ▼